Hepatic FMO3 Downregulation Contributes to the Metabolic Benefits of Vertical Sleeve Gastrectomy

Obesity · Published 2026-08-05 · DOI 10.1002/oby.70281

Authors (10)

Hai Yan, Chong Cao, Xiaozhuo Tan, Xianjue Huang, Yanyang Liu, Yuxiao Chu, Mengcheng He, Qiyuan Yao, Rong Hua, Yikai Shao

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Yan, H., Cao, C., Tan, X., et al. (2026). Hepatic FMO3 Downregulation Contributes to the Metabolic Benefits of Vertical Sleeve Gastrectomy. Obesity. https://doi.org/10.1002/oby.70281

Related articles

• Weight Change Between Pregnancies and Mortality Over 50 Years of Follow‐Up · Obesity · 2026 · Same journal
• The Lipid Droplet–Associated Hydrolase Is Associated With Obesity and Adipose Tissue Inflammation in Children · Obesity · 2026 · Same journal
• Trends in Diagnosing Obesity: The CALOR Study · Obesity · 2026 · Same journal
• ObesityWeek ® 2025—Reflecting on an Exciting Time in Obesity Research and Treatment · Obesity · 2026 · Same journal
• Health Care Costs and Use of Patients Prescribed Four Different Obesity Medications · Obesity · 2026 · Same journal
• Interaction Between Genetic Risk and Parental Feeding Practices in the Prediction of Overweight Across Adolescence · Obesity · 2026 · Same journal
• G Protein‐Coupled Receptor 17 (Gpr17) Enhances Leptin and Insulin Sensitivity in Lean and Obese Mouse Models · Obesity · 2026 · Same journal
• Navigating the Numerous Frameworks for Obesity Care · Obesity · 2026 · Same journal
• Real‐World Effectiveness of Semaglutide and Tirzepatide Compared With Bariatric Surgery · Obesity · 2026 · Same journal
• Weight‐Related Self‐Esteem, Group Behavioral Therapy, and Weight Loss · Obesity · 2026 · Same journal